Shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.50.
RNN has been the subject of a number of research reports. Zacks Investment Research upgraded Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research report on Friday, November 10th. HC Wainwright reiterated a “buy” rating and issued a $19.50 price objective on shares of Rexahn Pharmaceuticals in a research report on Monday, November 6th. Finally, ValuEngine raised Rexahn Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, November 2nd.
An institutional investor recently bought a new position in Rexahn Pharmaceuticals stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 49,167 shares of the company’s stock, valued at approximately $119,000. Zurcher Kantonalbank Zurich Cantonalbank owned approximately 0.16% of Rexahn Pharmaceuticals at the end of the most recent reporting period.
Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last announced its quarterly earnings data on Monday, November 6th. The company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.06.
TRADEMARK VIOLATION NOTICE: “Rexahn Pharmaceuticals, Inc. (RNN) Given Consensus Recommendation of “Buy” by Analysts” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/08/rexahn-pharmaceuticals-inc-rnn-given-consensus-recommendation-of-buy-by-analysts.html.
Rexahn Pharmaceuticals Company Profile
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.